Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference
September 02, 2022 12:32 PM Eastern Daylight Time
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that members of its senior leadership team will participate in one-on-one meetings with investors at the upcoming Citi 17th Annual BioPharma Conference taking place on September 7-8, 2022, in Boston, MA.
For additional information or to schedule a one-on-one meeting with members of the Oak Hill management team, please contact your Citi representative.
About Oak Hill Bio
Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The company, which has operations in the United States and United Kingdom, was launched to develop a pipeline of six promising clinical-stage and preclinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited (“Takeda”). For more information on Oak Hill Bio, visit the company’s website at www.oakhillbio.com.
Contacts:
Investors
Josh Distler
Oak Hill Bio
josh.distler@oakhillbio.com
Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
212-362-1200
Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936